Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XIGDUO Extended Release (XR) (DAPAGLIFLOZIN/METFORMIN XR FDC) Regulatory Postmarketing Surveillance To Observe Safety and Effectiveness Of XigduoXR (Registered) In Korean Patients

NCT03038789 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03038789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03038789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XIGDUO Extended Release (XR) (DAPAGLIFLOZIN/METFORMIN XR FDC) Regulatory Postmarketing Surveillance To Observe Safety and Effectiveness Of XigduoXR (Registered) In Korean Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 20, 2017
Completion date
August 30, 2019
Enrollment
623 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

adult patients with type 2 diabetes mellitus